Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin gamma 2, smooth muscle (ACTG2) is a member of the actin family of highly conserved cytoskeletal proteins. Specifically, ACTG2 encodes the smooth muscle–specific γ2 actin isoform that is critical for the formation and function of contractile filaments in enteric and visceral smooth muscle cells, such as those of the gastrointestinal and urinary tracts[1][2][3][4][6]. This protein is essential for the contraction required to move food through the intestines and expel urine from the bladder[1][2][3]. Mutations in ACTG2 disrupt filament polymerization, resulting in impaired muscle contractility and visceral myopathies like MMIHS and familial visceral myopathy, which present as severe GI and urinary dysmotility[1][3][5][7]. ACTG2 is not a drug target, but its variant status can serve as a diagnostic biomarker for visceral myopathies[5].
Not applicable; no drugs directly target ACTG2
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actin gamma 2, smooth muscle (ACTG2).